drugset

Drugs / [225Ac]Ac-AKY-1189

Follow last change Feb 2026 re-read 3 minutes ago

[225Ac]Ac-AKY-1189

Other / unclassified

Developed for: cervical adenocarcinoma · colorectal adenocarcinoma · head and neck cancer · hormone receptor-positive breast cancer · non-small cell lung carcinoma · triple-negative breast carcinoma · urothelial carcinoma
Investigated by: Aktis Oncology, Inc.

Trials 1

today NCT07020117 · Ph 1

202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07020117	Aug 2025 → Dec 2027 expected	cervical adenocarcinoma, colorectal adenocarcinoma, head and neck cancer, hormone receptor-positive breast cancer +3	Aktis Oncology, Inc.	Recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2024-10-25	Aktis Oncology, Inc.	Results Poster Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024 titled, “Discovery and pre-clinical development of AKY-1189, a potent and selective Nectin-4 miniprotein binder optimized for use as a targeted radiopharmaceutical.” aktisoncology.com ↗

All press releases naming this drug 2 releases

Date	Issuer	Release
2026-02-27	Aktis Oncology, Inc.	Poster presentation at the ASCO Genitourinary Cancers Symposium titled, “[225Ac]Ac-AKY-1189, a Nectin-4-Targeted Radiopharmaceutical, in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors: Phase 1b NECTINIUM-2 Study” aktisoncology.com ↗
2024-10-25	Aktis Oncology, Inc.	Poster Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024 titled, “Discovery and pre-clinical development of AKY-1189, a potent and selective Nectin-4 miniprotein binder optimized for use as a targeted radiopharmaceutical.” aktisoncology.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	[225Ac]Ac-AKY-1189	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07020117 ↗
Modality	Other / unclassified	“Nectin-4 radiopharmaceutical” NCT07020117 ↗